The WHO has recently released guidelines regarding
management of children up to 18 years of age who have been victims of
sexual abuse. The problem is ubiquitous. A study in 2011 states that 18%
of girls and 8% of boys worldwide have suffered sexual abuse. The key
message is to put the interests of the child first. Ensuring safety,
offering confidentiality, presenting all possible choices, being
especially sensitive to additional issues like gender identity and
disabilities, and providing care without discrimination should be the
main goals.
The recommendations state that care givers should be
careful to avoid additional trauma while taking history, performing
examination and documenting data. Children who present within 72 hours
must be offered post-exposure prophylaxis to prevent HIV. Emergency
contraception must be offered to girls who have presented within 5 days.
Hepatitis B and HPV vaccine may be offered according to national
guidelines. Cognitive behavioral therapy is advised for children who
manifest post-traumatic stress disorder.
The consequences of sexual abuse are both immediate
as well as long-term. Till we are able to ensure a safe society for
children to grow up in, the guidelines will help in improving immediate
care of these traumatized children. (http://www.who.int/reproductivehealth/topics/violence/clinical-response-csa/en/)
Indian is Deputy Director at WHO
Dr Soumya Swaminathan, a pediatrician by training,
has been appointed to be Deputy Director of Programs in the WHO. This
will be the highest post ever held by an Indian in the WHO. Dr
Swaminathan is an alumnus of the Armed Forces Medical College and the
All India Institute of Medical Sciences. She is well known
internationally for her work on tuberculosis, and she has been the
Director of the National Institute of Research in Tuberculosis in
Chennai for several years. Since then she has moved on to being the
Director General of Indian Council of Medical Research (ICMR) and the
Secretary, Department of Health Research, Ministry of Health and Family
Welfare.
She has undertaken large trials to test various
strategies to deliver anti-tubercular therapy in the community,
especially underserved areas. She has also been instrumental in scaling
up the use of molecular diagnostics for TB surveillance and care. Most
recently she is part of the TB Zero City Project, which aims to create
"Islands of elimination" working with local governments, institutions
and grassroots associations. Thirty years of dedicated clinical research
in the important area of tuberculosis will hold her in good stead to
handle the onerous responsibilities now resting on her capable
shoulders. (The Hindu 4 November 2017)
Mandatory Clinical Trial Data Reporting
In 2007, the ICMR launched a free online Clinical
Trials Registry of India (CTRI), hosted at the ICMR’s National Institute
of Medical Statistics (http://nims-icmr.nic.in, www.ctri.nic.in). Since
2009, the Drugs Controller General of India (DCGI) has mandated
registration of clinical trials in the CTRI. Further, editors of
biomedical journals of 11 major journals of India have declared that
only registered trials would be considered for publication.
From April 2018, it will become compulsory for all
organizations and persons who have registered for clinical trials to
disclose outcomes of the trials within one year of completion. The move
has been made to increase the visibility of negative trial results.
Trials with positive results are far more likely to come to public view
and be published, whereas negative data are equally important to get a
big picture of the truth.
Organizations which do not comply will be
blacklisted, which means future trials will not be registered, and they
will not be considered for grants. The number of trials registered with
CTRI has risen steadily from 545 in 2009 to 1,327 in 2017. The CTRI has
8,950 trials registered as on June 30, 2017, of which 2,036 have been
completed and 28 terminated. (The Indian Express 23 November 2017).
Drug-resistant Malaria in South East Asia
Artemisinin combination therapies (ACTs) have become
the cornerstone of the treatment of falciparum malaria throughout the
malaria endemic world. Artesunate resistance in falciparum malaria was
first documented in Western Cambodia in 2007. Since then,
Dihydroartemisinin- piperaquine combination has been the first line
therapy for falciparum malaria in Cambodia. However, over the past 10
years, the drug-resistant strain has spread to northeastern Thailand,
southern Laos and eastern Myanmar.
Recent work by Prof Arjen Dondorp and his colleagues
in the Oxford Tropical Medicine Research Unit in Bangkok has revealed
some sinister developments. Falciparum has now become resistant to both
artermisinin and piperaquine. Cambodia has now switched over to the
artemisinin-mefloquin combination that is still effective.
The number of malaria cases in South East Asia are
relatively few, compared to Africa which accounts for 92% of cases. In
the 1950’s and 1960’s, there were two waves of drug-resistant malaria
when resistance to chloroquine and sulphadoxine-pyrimethamine swept from
South East Asia to the rest of Asia and Africa resulting in huge number
of deaths.
The fear is of history repeating itself, unless artimisinin-resistant
malaria is contained and eradicated in Cambodia, Thailand and Vietnam. (The
Lancet Infectious Diseases October 2017).